Butyrate has dual roles in normal and tumor colonocytes. In normal cells, it serves as an energy source, metabolized to acetyl-CoA in the Krebs cycle, promoting cell proliferation. In tumor cells, due to the Warburg effect, butyrate does not enter the Krebs cycle but instead modulates gene expression through HDAC inhibition, leading to downregulation of Cyclin-dependent kinase inhibitor 1 (p21Cip1/Waf1) and Cyclin-dependent kinase inhibitor 1B (p27Kip1), inhibiting cell proliferation, and providing cancer-related benefits
Butyrate is taken up by e.g., colonocytes and converted into butyryl-CoA, then into acetyl-CoA. Acetyl-CoA is a key substrate for the Krebs cycle, where it fuels cellular respiration for ATP production. This conversion ties butyrate directly into energy metabolism via the TCA cycle. It is not available to the nucleus.
Butyrate is the preferred energy source for colon epithelial cells, and its deficiency may impair gastrointestinal function
G-Protein Coupled Receptor 41 (GPR41) is expressed in intestinal Enteroendocrine Cells (EEC), stimulating the release of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). PYY can regulate intestinal movement, affecting the absorption of nutrients in the intestine, and GLP-1 can regulate satiety.
Butyrate facilitates the maturation of the colonic mucus barrier and counteracts the growth of pathobionts
Butyrate is linked to numerous health benefits. It provides energy to colonocytes.
Butyrate activates PPAR-gamma Signal transduction in human epithelial cells () to drive the metabolism of surface colonocytes toward mitochondrial beta-oxidation (; 36-37), which is essential for maintaining physiologic hypoxia
Increased butyrate in humans is associated with improved glucose tolerance. In a clinical trial, individuals on a high-fiber diet showed increased butyrate levels and lower Hemoglobin A1c, which is a measure of blood glucose control
Butyrate also appears to ameliorate insulin sensitivity by stimulating the secretion of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP)) incretins. Butyrate enhances the expression of the anorexigenic adipokine leptin
Butyrate suppresses intestinal inflammation and oxidative stress, while protecting the intestinal epithelial barrier via its HDAC inhibitor role
Butyrate / Butyric acid is considered to be anti-carcinogenic and anti-inflammatory.
Mechanistic studies in animal models showed beneficial effects of Butyrate / Butyric acid in maintaining GI barrier integrity, quenching oxygen at the epithelial interface, and exerting immune-modulating effects.
Butyrate blocks dendritic cell generation. They don't affect granulocytes. This depends on the transporter Sodium-Coupled Monocarboxylate Transporter 1 (SMCT1). It moves butyrate into cells. These metabolites inhibit histone deacetylases.
Butyrate is known to be a primary energy source for colonocytes
Butyrate, but not acetate or propionate, inhibited lymphocyte proliferation and IL-2 production in rats
see also:
Biological effects / Functions & Short-Chain Fatty Acids (SCFAs)
Butyrate / Butyric acid & Cancer / Tumors
Butyrate / Butyric acid & Dendritic cells (DCs)
Butyrate / Butyric acid & Histone deacetylases (HDACs)
Butyrate / Butyric acid & Histone Deacetylase (HDAC) inhibition
Butyrate / Butyric acid & Colitis / Intestinal inflammation
Butyrate / Butyric acid & Lipogenesis
Butyrate / Butyric acid & Sodium-Coupled Monocarboxylate Transporter 1 (SMCT1)
Butyrate-producing bacteria
Energy Source & Short-Chain Fatty Acids (SCFAs)
Gut microbiota & Type 2 Diabetes (T2D)
Gut microbiota & Metabolic diseases / Metabolic disorders
Short-chain Fatty Acids (SCFAs) & Type 2 Diabetes (T2D)